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Abstract A family of proliferin genes was discovered on a
microarray analysis of hematopoiesis supportive stromal cell
lines. Proliferin-2 (PLF2) increased the frequency of long-
term culture-initiating cells (LTC-IC) from 1 in 340 to 1 in
256 of the primary hematopoietic stem cell (HSC)-enriched
bone marrow cells grown on MS5.1 feeder layer. A repeat using
AFT024 feeder layer also showed a similar increase in LTC-IC
(from 1 in 386 cells to 1 in 260 cells). The clonogenic output of
the LTC-ICs was also increased signi¢cantly. The growth of
various hematopoietic and stromal cell lines treated with
PLF2 was found to increase by 4^27%, as measured by cell
count and DNA synthesis assay. These ¢ndings open up the
possibility of using PLF2 as a new member of the growth factor
cocktails for the ex vivo expansion of HSC.
6 2003 Published by Elsevier B.V. on behalf of the Federation
of European Biochemical Societies.
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1. Introduction
The use of stem cells for regenerative medicine and cell-
based therapies is currently under intense exploration [1],
and one of the best characterized of these are hematopoietic
stem cells (HSC) [2]. HSC have important usage in a variety
of clinical settings. They can be used as grafts to prevent
chemotherapy-induced pancytopenia, as support to patients
undergoing high-dose chemotherapy, as replacement gene
therapy, and in immunotherapy by generating a large volume
of immunologically active cells with anti-tumor activity [3].
The limitation to these applications has been in obtaining
su⁄cient amounts of HSC or the total amount of de¢ned
target cells.
Adult bone marrow and fetal liver consist of both hemato-
poietic cells and the stroma needed to maintain hematopoie-
sis. HSC are closely associated with discrete in vivo stromal
microenvironments. Recent e¡orts to understand the stromal
microenvironments [4,5] have revealed that they involve a
complex multi-component molecular network. The molecular
signals that regulate and promote proliferation and other cell
fates are produced by the cellular component of this micro-
environment, which consists of ¢broblasts, preadipocytes, en-
dothelial cells and macrophages [6]. These microenvironments
are thought to provide a rich milieu of molecular signals that
mediate HSC di¡erentiation and self-renewal through a com-
bination of cytokine production, extracellular matrix compo-
nent deposition, and cell^cell adhesion contacts with hemato-
poietic cells [6]. Identi¢cation and characterization of these
regulators is an active area of research [4,5,7,8]. An under-
standing of the functions of these molecules will be the key to
unlock the in vitro HSC expansion problem and to enhance
bioengineering strategies to expand HSC in culture [3].
We used high-density microarrays in an e¡ort to identify
the various secreted and membrane molecules expressed by
di¡erent stromal cell lines. A list of molecules associated
with supportive activities was obtained by comparing support-
ing and non-supporting stromal cell lines. A family of glyco-
proteins known as the proliferins (PLFs) was discovered on
the list. The PLFs comprise a group of four homologous
proteins [PLF1, PLF2, PLF3, and PLF-related protein
(PRP)] [9^13]. All forms of PLF show high similarity in their
amino acid sequences. PLFs in adult mice has been shown to
be expressed in the placenta, tail and ear skin, hair follicles,
and small intestine [13^15]. Except for PRP, the presence of
PLFs in these tissues is associated with growth (e.g. hair fol-
licles and uterus), angiogenesis, and wound healing in the skin
[13,15,16]. The homology between PLF and prolactin (31%
sequence identity) puts them in the prolactin/somatotropin/
placental lactogen family of peptide hormones. The growth-
promoting e¡ects of PLFs have not been demonstrated in
adult HSC.
The above ¢ndings have led to the hypothesis that PLFs
may be an autocrine or paracrine growth factor that regulates
growth and di¡erentiation of speci¢c cells [16]. With this hy-
pothesis in mind, we looked for PLF2 binding in hemato-
poietic progenitor cells and stromal cells, e¡ects on the ex
vivo expansion of primary adult HSC, and subsequently mi-
togenic activities in various cell lines.
2. Materials and methods
2.1. Cell lines
Mouse hematopoietic progenitor cell lines used in the study were
EML and FDCP.Mix. EML is a bone marrow-derived progenitor cell
line capable of di¡erentiation along both lymphoid and myelo-ery-
throid pathways [17], while FDCP.Mix is another bone marrow-de-
rived multipotential progenitor cell line [18]. For comparison pur-
poses, M1 cells were used as a mature hematopoietic cell type
capable only of di¡erentiation along a single pathway [19]. The cell
lines MS5.1 [20] and S17 [21] are bone marrow-derived stromal cells
capable of maintaining primitive hematopoietic cells. OP9 [22] are
stromal cells derived from mouse newborn calvaria. Two fetal liver-
derived stromal cell lines used in this study were AFT024 and BFC012
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[7]. The maintenance and culture conditions of the cells were as de-
scribed.
2.2. Isolation of primary bone marrow cells and enrichment for HSC
Total bone marrow was obtained from the femora of 8^12-week-old
C57BL/6J mice and suspended in IMDM with 2% fetal bovine serum
(FBS). Animals were killed by cervical dislocation; the procedure was
approved by the Animal Holding Unit of the local institution. Frac-
tions enriched with HSC were obtained by negative selection from the
total bone marrow using the StemSep system (StemCell Technolo-
gies). Brie£y, single cell suspensions were obtained from total bone
marrow by vigorous pipetting. Mature hematopoietic cells were im-
munomagnetically labeled using a cocktail of antibodies (CD5,
CD45R, CD11b, Ter119, Gr-1 and 7-4) directed against lineage
markers. The cells were then passed through a magnetic column where
the labeled cells (lineage-positive, Linþ) would be captured and HSC-
enriched cells (lineage-negative, Lin3) would be collected from the
£ow-through.
2.3. Expression array analysis
Total RNA was extracted from the stromal cells using the commer-
cial reagent Trizol (Invitrogen). cRNA synthesis and hybridization
onto A¡ymetrix murine GeneChip MG_U74A ver2 were done ac-
cording to the manufacturer’s instructions. Expression pro¢ling for
each cell line was performed twice and the average expression level
analyzed by the A¡ymetrix Microarray Suite 5.0 software. The mea-
sured mRNA expression levels from each cell type were normalized by
dividing the individual mRNA value by the average mRNA expres-
sion of the cell, and analyzed using the GeneSpring software (Silicon
Genetics). This allowed the comparison of mRNA expression across
the di¡erent stromal cells.
2.4. Reverse transcription and semi-quantitative polymerase chain
reaction (PCR)
The mRNA expression of PLF2 was con¢rmed by reverse tran-
scription and semi-quantitative PCR analysis. Total RNA (5 Wg)
from the cells was reverse transcribed into ¢rst-strand cDNA using
oligo-dT primers (SuperScript First Strand Synthesis System, Invitro-
gen) according to the manufacturer’s instruction. The ¢rst-strand
cDNA products were stored at 320‡C for subsequent studies. Primers
for PLF2 (forward primer: 5P-ACAGCTAAGCCTGGGTAG-
GACTCT-3P ; reverse primer: 5P-GATATTTCAGAAGCAGAGCA-
CATGA-3P) were synthesized (Proligo). A housekeeping gene, glycer-
aldehyde-3-phosphate dehydrogenase (GAPDH), was used as control
in the ampli¢cation. The primer sequences for GAPDH were 5P-
ATGGTGAAGGTCGGCGTGAAC-3P for the forward primer and
5P-TTACTCCTTGGAGGCCATGTAGGC-3P for the reverse primer
(Proligo). The ampli¢ed full-length products of both PLF2 and
GAPDH spanned from the 5P-untranslated region to the 3P-untrans-
lated region of the genes. The semi-quantitative cycling parameters
were 94‡C for 1 min, followed by 25^35 cycles of 94‡C for 30 s,
58‡C for 30 s, 72‡C for 1 min. This was to determine the pre-satu-
ration linear ampli¢cation cycles, and the midpoint of the linear am-
pli¢cation was chosen for semi-quantitative analysis.
2.5. Baculovirus expression system
The degree of PLF glycosylation may determine di¡erences in the
functional interactions and binding with PLF receptors in vivo [16].
PLF2 was hence expressed in a baculovirus system for this experi-
ment. The full-length PLF2 gene was cloned and expressed in Hi5
insect cells using the pFastBac system (Invitrogen). Recombinant
PLF2 from the culture supernatant was puri¢ed through the His tag
using a commercial Ni-NTA column (Qiagen). Puri¢ed recombinant
PLF2 was resolved on a 12% sodium dodecyl sulfate^polyacrylamide
gel to analyze its purity and integrity. The concentration of puri¢ed
protein was quanti¢ed using a colorimetry method (Coomassie Plus,
Pierce).
2.6. Flow cytometry analysis
Cells were washed and resuspended in phosphate-bu¡ered saline
(PBS) with 2% bovine serum albumin (BSA) before incubation for
3 h at room temperature with 100 nM puri¢ed recombinant PLF2.
After that, the cells were washed and blocked with 5% rabbit serum
for 15 min at 4‡C prior to staining with £uorescein isothiocyanate
(FITC)-conjugated antibody against human IgG1 (Fc) (Dako) for
15^20 min at 4‡C. The cells were washed and resuspended in PBS
with 2% BSA and 1 Wg/ml propidium iodide. Stained cells were ana-
lyzed by FACSCalibur (Becton Dickinson) using the CellQuest soft-
ware (Becton Dickinson). For primary hematopoietic cells, the phy-
coerythrin-conjugated antibody (Becton Dickinson) against stem cell
antigen 1 (Sca1) was also used to identify the primitive hematopoietic
cells from the HSC-enriched bone marrow extracts. All antibodies
used were diluted to the manufacturers’ speci¢ed concentrations prior
to the £ow cytometry experiments.
2.7. Assays for long-term culture-initiating cells (LTC-IC) and
colony-forming cells (CFC)
The LTC-IC content of the HSC-enriched bone marrow cells was
determined by a limiting dilution assay (LDA). Brie£y, a feeder layer
for LTC-IC from bone marrow was prepared using MS5.1 or AFT024
cells. The feeder layer was plated onto gelatinized 96-well plates at
3U104 cells/well. After the cells had attached overnight, mitomycin C
(Sigma) at 0.75 Wg/ml (optimal predetermined concentration) was
added to the cells to prevent further cell growth [23]. Mitomycin C
was washed away after 3 h of incubation with the cells. LDA was
performed using murine myeloid long-term culture medium (Myelo-
Cult, StemCell Technologies) supplemented with 1 WM hydrocortisone
sodium hemisuccinate (StemCell Technologies). HSC-enriched bone
marrow cells (isolated as stated above) were plated at varying cell
numbers onto the mitomycin C-treated feeder layer with 25 replicates
for each cell number. The cultures were maintained for 4 weeks at
33‡C and 5% CO2 with weekly half medium replacement. After 4
weeks, all the cells in the LTC were harvested by trypsinization and
resuspended in IMDM with 2% FBS. The cells in each well were
plated onto a 35-mm dish containing methylcellulose medium supple-
mented with transferrin, insulin, erythropoietin (EPO), interleukin
(IL)-3, IL-6 and stem cell factor (SCF) (MethoCult, StemCell Tech-
nologies). The colony formation culture was incubated at 37‡C and
5% CO2. The proportion of negative wells (wells containing no de-
tectable CFC) after 14 days was counted and analyzed to determine
the frequencies of LTC-IC from each input of cells. Clonogenic out-
put of the LTC-IC was determined by scoring the number of colonies
(containing v 30 cells each) in each positive well.
2.8. Cell proliferation and 5-bromo-2P-deoxyuridine (BrdU)
incorporation assays
To determine cell proliferation, cells were seeded at 1U104 per well
onto a 96-well plate. PLF2 was given to the cells at various concen-
trations and time intervals. The number of viable cells in each well
was counted using a hemocytometer after staining the cells with try-
pan blue (Sigma). For the BrdU incorporation assay, cells were seeded
at 5U103 per well onto a 96-well plate. These were incubated at 37‡C
for 48 h in the presence of 100 nM PLF2 prior to staining with 10 WM
BrdU (Cell Proliferation ELISA, BrdU Kit, Roche) for 2 h. The cells
were then washed, ¢xed, and the DNA denatured according to the
manufacturer’s instruction. The amount of incorporated BrdU was
detected colorimetrically using peroxidase-conjugated anti-BrdU anti-
body. The absorbance of the samples was measured at 450 nm with
reference wavelength at 690 nm. Both assays were carried out in ¢ve
replicates, and the means and S.E.M. were calculated. Statistical sig-
ni¢cance was determined using Student’s unpaired t-test.
2.9. Statistical analysis
All statistical analyses performed in this study (i.e. t-test, curve
¢tting, linear regression analysis, etc.) were carried out using the soft-
ware Prism ver3.03 (Graphpad Software). LDA analyses were per-
formed with the L-Calc software (Stem Cell Technologies) to deter-
mine the LTC-IC frequencies and 95% con¢dence intervals of ¢tted
lines.
3. Results
3.1. Expression pro¢les of the PLF family
In this project, we employed a large-scale genomic ap-
proach to dissect the hematopoietic microenvironment in the
hope of identifying regulators that mediate stem cell fates. In
general, the supporting cell types AFT024 [7], MS5.1 [20] and
S17 [21] had higher expressions of the PLFs compared to the
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non-supporting cell types BFC012 [7] and OP9 (Table 1).
None of the hematopoietic cell types expressed any PLF.
PLF2 had the highest mRNA expression among the PLF
family members. Thus, it was chosen for further character-
ization of its e¡ects in the hematopoietic system.
Expression pro¢les of PLF2 from the microarray analysis
were con¢rmed by reverse transcription and semi-quantitative
PCR. This method was chosen over the conventional North-
ern blot method as it permits detection of mRNA of all abun-
dance levels and is much faster than hybridization analyses.
Due to the low starting amount of single-stranded cDNA, a
trial PCR experiment was performed to 24^34 cycles with
two-cycle intervals. An aliquot of the PCR mixture at each
interval was electrophoresed on a 2% agarose gel. Exponential
phase of the PCR was determined visually and found to range
from 26 to 30 cycles. Saturation was found to begin after cycle
32. We chose to stop the PCR at cycle 28 for the semi-quan-
titative analysis of PLF2 cDNA level in various cell lines (Fig.
1). At this non-saturated cycle, the ampli¢ed products of
PLF2 were found to correlate well with the microarray anal-
ysis results in Table 1, thereby con¢rming the expression levels
of PLF2. Non-saturating PCR on normalized starting single-
stranded cDNA should give an accurate comparison of rela-
tive mRNA copy numbers [24,25].
3.2. PLF2 binding on hematopoietic and stromal cells
Puri¢ed recombinant PLF2 was tested for receptor binding
in the stromal and hematopoietic cells. PLF2 was found to
have greater binding to the EML hematopoietic progenitor
cells than to the mature M1 hematopoietic cells (Fig. 2A).
The bone marrow stromal cell line MS5.1 was found to
have a higher intensity of £uorescence resulting from binding
of FITC-labeled PLF2, suggesting the presence of more PLF2
receptors on these cells as compared to the fetal liver stromal
cell line AFT024. PLF2 binding to primary bone marrow
hematopoietic cells was also tested, where it seemed to bind
speci¢cally to the HSC-enriched (Lin3) fraction of the bone
marrow cells, but not to the Linþ cells (Fig. 2B). The ¢ndings
that PLF2 could bind to the stromal cells and HSC-enriched
Lin3 cells, but not to mature cells (M1 and Linþ cells) indi-
cate that PLF2 may play a role in early hematopoiesis even
though the speci¢c PLF2 receptor in the hematopoietic system
has not been identi¢ed.
Sca1 is a surface protein expressed on immature hemato-
poietic progenitor cells [26]. PLF2 identi¢ed a subpopulation
of Sca1-positive primary bone marrow cells and also a group
of cells negative for Sca1 (Fig. 2C). It is possible that PLF2 is
identifying a subset of multi-lineage HSC that is receptive to
long-term culture which may or may not be Sca1-positive. A
group of cells known as the ‘side population’ cells have pre-
viously been identi¢ed to have high repopulating activity and
multi-lineage potential despite the fact that only 75% of these
cells are Sca1-positive [27]. It is unclear at this stage whether
PLF2-positive cells are also within the ‘side population’ of
HSC.
3.3. E¡ects of PLF2 on the frequency of LTC-IC and
clonogenicity in HSC-enriched bone marrow cells
LDA was used to estimate the frequencies of LTC-IC in the
HSC-enriched bone marrow cells [28]. In this study, LDA was
performed on MS5.1 or AFT024 feeder layers. A linear rela-
tionship was obtained when the logarithm of the proportion
of negative cultures was plotted against the total number of
cells used to initiate each culture. The generalized linear model
was ¢tted by ¢nding the maximum likelihood using the New-
ton^Raphson method, and the goodness-of-¢t to the model
Table 1
mRNA expression pro¢les of the PLF family in stromal and hematopoietic cell lines
GenBank No. Proliferin AFT024 BFC012 MS5.1 OP9 S17
Normalized Flags Normalized Flags Normalized Flags Normalized Flags Normalized Flags
A: Stromal cells
K02245 Proliferin-1 0.27 P 0.02 A 1.75 P 0.02 A 1.55 P
K03235 Proliferin-2 1.07 P 0.03 A 7.68 P 0.01 A 16.84 P
X16009 Proliferin-3 0.66 P 0.08 A 7.92 P 0.10 A 14.94 P
K03237 PRP 0.01 A 0.01 A 0.01 A 0.01 A 0.01 P
B: Hematopoietic cells M1 EML FDCP.Mix
Normalized Flags Normalized Flags Normalized Flags
K02245 Proliferin-1 0.01 A 0.01 A 0.02 A
K03235 Proliferin-2 0.10 A 0.01 A 0.01 A
X16009 Proliferin-3 0.07 A 0.10 A 0.13 A
K03237 PRP 0.01 A 0.01 A 0.01 A
The expression levels were normalized against the total mRNA expression of each cell type. Absence (A) or presence (P) calls for a gene were
determined by the A¡ymetrix Microarray Suite software.
Fig. 1. Semi-quantitative PCR analysis of PLF2 gene expression in
the stromal and hematopoietic cell lines. Equal amounts of ¢rst-
strand cDNA product were used in the analysis. The GAPDH gene
was used as a housekeeping gene to show equal ampli¢cation in all
cell types. The images show the ampli¢cation products on a 1%
agarose gel after 28 cycles.
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was assessed by the generalized Pearson chi-square. The LTC-
IC frequency in the HSC-enriched bone marrow cells would
then correspond to the derived cell dose at which 37% of the
cultures yielded a negative response. Using MS5.1 as the
feeder layer (Fig. 3A), the frequency of LTC-IC was 1 per
340 in C57BL/6 mouse-derived HSC-enriched bone marrow
cells. A 1.3-fold (P=0.235) increase in the frequency of
LTC-IC (from 1 in 340 to 1 in 256 cells) was observed
when 100 nM PLF2 was added to the medium. A similar
experiment repeated with AFT024 as the feeder layer (Fig.
3B) showed an increase of 1.5-fold (P=0.06) in LTC-IC
(from 1 in 386 to 1 in 260 cells).
The number of clones (v 30 cells) in the positive CFC wells
in each dilution was also counted and plotted against the
initial cell seeding in LTC (Fig. 4). For the experiment using
AFT024 as the feeder layer, the test for the null hypothesis
that the two ¢tted lines were parallel was rejected (P6 0.001
by analysis of covariance). This showed that the increase in
clonogenic output after PLF2 treatment was in direct propor-
tion to the increase in LTC-IC frequency. The slopes of the
two ¢tted lines in the experiment using MS5.1 as the feeder
layer were not signi¢cantly di¡erent from each other
(P=0.609). A second null hypothesis that the lines were iden-
tical was tested. The two ¢tted lines were found to be distinct
Fig. 2. Receptor binding of PLF2 on the stromal and hematopoietic cells. Binding of PLF2 to cells was detected by FITC-labeled secondary
antibody using the FL-1 channel and is displayed as frequency histograms (A,B). Dot plots of Sca1 (FL-2 channel) and PLF2 (FL-1 channel)
binding in primary bone marrow cells are also shown (C).
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but parallel to each other (P=0.004), suggesting that the ef-
fect of PLF2 in increasing clonogenicity of LTC-IC cultured
with the MS5.1 feeder layer was signi¢cant but low. These
¢ndings demonstrate that di¡erent stromal cells had di¡erent
supporting activity on the long-term culture of HSC, with
AFT024 supporting a higher number of clonogenic cells as
compared to MS5.1 stromal cells.
Progenies that di¡erentiated along di¡erent lineages were
noted when the colonies were counted. The type of lineage
observed was consistent with the type of growth factor (EPO,
IL-3, IL-6 and SCF) incorporated into the methylcellulose
medium. The colonies were almost exclusively of the multi-
lineage potential type, i.e. colony-forming unit granulocyte-
macrophage, and CFU-granulocyte, erythroid, macrophage,
megakaryocyte, showing that LTC-ICs expanded by PLF2
still retained the capacity to di¡erentiate along multiple line-
ages. An accurate quantitation of all types of progenies was
not carried out due to di⁄culties in accurately assigning lin-
eages to the clones.
3.4. E¡ects of PLF2 on hematopoietic and stromal cell lines
Next, we investigated the proliferation and pro-survival ef-
fects of PLF2 in the hematopoietic system. Initially, PLF2 was
given daily or on alternate days to the cells, and the cell
number was determined after 97 h. It was observed that
PLF2 exerted an inhibitory e¡ect on cell number (by 9^
65%) on the various hematopoietic progenitor and stromal
cell lines studied (data not shown). The successive administra-
tion probably caused a continual receptor stimulation result-
ing in down-regulation via internalization and degradation of
the signal receptors. This made the cells refractory to addi-
tional PLF2. PLF2 was also given at various concentrations
to the above cell lines. Concentrations lower than 100 nM did
not seem to induce a signi¢cant increase in cell number or
DNA synthesis as measured by BrdU incorporation assays
(data not shown).
For subsequent experiments, PLF2 at 100 nM was admin-
istered at the commencement of the test and only during me-
dium change after 96^120 h. There was an increase in bone
marrow stromal MS5.1 cell number by 26.7% at 96 h after
treatment with 100 nM PLF2 (P=0.116) (Fig. 5). For the
AFT024 fetal liver stromal cells, PLF2 at 100 nM stimulated
an increase of 7.5% in cell number after 96 h (P=0.258).
PLF2 was also observed to have a slight proliferative e¡ect
on the EML hematopoietic progenitor cells (a 4.2% increase
in cell number after 96 h, P0.416).
The e¡ects of PLF2 on cells were further con¢rmed using
the BrdU incorporation assay. The assay speci¢cally measures
active DNA synthesis during S phase of the cell cycle. The
BrdU incorporation correlated well with the above cell count
Fig. 2 (Continued).
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assay. MS5.1 stromal cells showed a signi¢cant 1.6-fold in-
crease in DNA synthesis after treatment with PLF2
(P=0.014), while the AFT024 stromal cells also showed a
signi¢cant 1.7-fold increase in DNA synthesis (P=0.034).
From the above observations, PLF2 demonstrates an auto-
crine stimulatory e¡ect on the stromal cells.
The EML hematopoietic progenitor cells treated with 100
nM PLF2 had higher BrdU incorporation (by 1.13-fold) as
compared to untreated cells (P=0.479). EML is a factor-de-
pendent hematopoietic cell line (dependent on SCF). The cells
will undergo cell death 24^48 h after withdrawal of the growth
factors [17], shown here as a reduction in DNA synthesis. The
present study shows that even though PLF2 can increase
DNA synthesis in the hematopoietic progenitor cell line, it
could not exert its e¡ect without the presence of the required
growth factor.
4. Discussion
PLFs show high amino acid sequence similarity among the
members, and to the prolactin and placental lactogen. The
PLFs’ amino acid sequence conservation is high across the
mammalian and reptilian kingdoms except for human, where
there is no signi¢cant PLF homologue. On the other hand,
domain homology search using Pfam revealed that it belongs
to the somatotropin hormone family. The PLF2 amino acid
sequence from 12 to 224 showed signi¢cant domain match to
the human lactogen and somatotropin (Pfam score = 348.5, E
value= 5.9e-102). The somatotropin hormone family consists
of somatotropin, which plays an important role in growth
control, choriomammotropin (lactogen), its placental ana-
logue; prolactin, which promotes lactation in the mammary
gland, and placental prolactin-related proteins [29] ; proliferin
and proliferin-related protein [12] ; and somatolactin from
various ¢shes [30]. PLF has been shown to bind to the insu-
lin-like growth factor II (IGF-II)/mannose-6-phosphate
(M6P) receptor in endothelial cells [31]. PLF can also bind
with high a⁄nity and speci¢city to an unknown speci¢c re-
ceptor in the uterus that is distinct from the IGF-II/M6P
receptor, and is able to mediate cell proliferation [32]. This
unknown receptor may also be responsible for PLF transport
though the yolk sac, which appears to be independent of the
IGF-II/M6P receptor [33]. In all instances, binding of PLF is
associated with cell growth and proliferation.
The dissociation constant, Kd, for PLF binding in uterine
tissue [32] and fetal liver [34] is low (Kd value ranging from 0.6
Fig. 3. Limiting dilution analysis of LTC-IC frequency in 100 nM PLF2-treated HSC-enriched bone marrow cells grown on MS5.1 (A) and
AFT024 (B) stromal layers. The 95% con¢dence interval is shown as the dotted lines on either side of the ¢tted line. HSC-enriched cells grown
on the MS5.1 feeder layer had a LTC-IC frequency of 1 in 340 cells (95% con¢dence interval: 1 in 244 to 1 in 473 cells), while those receiving
PLF2 had a LTC-IC frequency of 1 in 256 cells (95% con¢dence interval: 1 in 185 to 1 in 355 cells). HSC-enriched cells grown on the
AFT024 feeder layer had a LTC-IC frequency of 1 in 386 cells (95% con¢dence interval: 1 in 287 to 1 in 519 cells), while those receiving
PLF2 had a LTC-IC frequency of 1 in 260 cells (95% con¢dence interval: 1 in 198 to 1 in 342 cells).
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to 2.0 nM). This suggests that PLF is a potent growth factor
that can exert an e¡ect at pico- to nanomolar concentrations.
The maximal binding of PLF is observed in the femtomolar
range per milligram uterine tissue-derived membrane protein
[32], indicating that the numbers of PLF receptor are low per
cell. This correlates well with our observation from £ow cy-
tometry analysis that the PLF2 FITC intensity shift pro¢le is
low for most cell types tested.
LTC-ICs are closely related to, if not highly overlapping
with, transplantable stem cells. They are distinguished by their
ability to generate multi-lineage colonies for at least 5 weeks
in liquid cultures containing a stromal layer [35]. The in vivo
competitive repopulation unit (CRU) assay tests the ability of
a cell to generate and sustain production of both mature
myeloid and lymphoid cells for many weeks after being trans-
planted into a hematologically compromised host. The assay
has been adopted as an operationally useful, albeit cumber-
some, de¢nition for assigning a cell to the stem cell compart-
ment. Until a simpler assay is developed, the test for the
frequency of LTC-IC remains a useful alternative. Both the
in vitro LTC-IC and the in vivo CRU assays are known to
identify closely related populations in normal murine and hu-
man hematopoietic tissues of either adult [35] or fetal [36]
origin.
The moderate e¡ect of PLF2 is probably not unexpected as
HSC are exposed in situ to many di¡erent growth factors.
Our current knowledge of how di¡erent soluble growth fac-
tors control the fate of HSC is deduced from in vitro studies,
where the growth factors may not necessarily be introduced at
physiological concentrations, in the correct ratios, or at the
appropriate times. Some of the growth factors that have been
shown to enhance the proliferation of HSC are £t3, SCF,
Fig. 4. Clonogenicity of LTC-IC administered 100 nM PLF2 grown
on MS5.1 (A) and AFT024 (B) feeder layers. LTC-IC grown on the
MS5.1 feeder layer showed a distinct and signi¢cant increase
(P=0.004) in clonogenicity when given PLF2. Similarly, LTC-IC
grown on the AFT024 feeder layer showed a very signi¢cant in-
crease (P6 0.001) in clonogenicity when given PLF2. From the
slopes of the data sets, the increase in clonogenicity with AFT024
as the feeder layer was more drastic compared to using MS5.1 as
the feeder layer.
Fig. 5. E¡ects of PLF2 on cell proliferation. Viable cell count (A)
and BrdU assays (B) were performed 96 h after administration of
100 nM PLF2. The controls were cells without PLF2 treatment. Re-
sults are shown as means with S.E.M. indicated by the error bars.
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EPO, IL-6 and thrombopoietin [28,37]. Their e¡ects are de-
pendent on both the concentration of each component and
the speci¢c combinations of these growth factors. The combi-
nation of SCF, IL-3, IL-6 and soluble IL-6 receptor [38,39] is
among the well-known cocktails for ex vivo expansion of
human HSC. Thus, the use of a single growth factor may
not allow full demonstration of its capacity. Further e¡ort
to delineate and optimize the activity of PLF2, alone or in
conjunction with pre-existing growth factor cocktails, for the
in vitro expansion of HSC is therefore warranted.
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